Purchase this article with an account.
A. H. Krauss, C. A. Toris, M. E. Kallberg, K. Gelatt, G. Prasanna, F. Impagnatiello, V. Chiroli, W. K. Chong, S. Carreiro, E. Ongini; Ocular Hypotensive Activity of PF-3187207, a Nitric Oxide Donating Prostaglandin Analog, in Preclinical Models. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1471.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the ocular hypotensive activity and distribution of PF-3187207 following topical administration.
The effect on IOP was investigated in cynomolgus primates with laser-induced ocular hypertension, glaucomatous Beagle dogs and rabbits using a model of transient ocular hypertension induced by intracameral administration of hypertonic saline. Nitric oxide (NO) and cGMP levels were determined in rabbit eyes following topical administration. PF-3187207 activity was compared with that of latanoprost as a reference drug.
PF-3187207 stimulated cGMP formation in PC-12 and HEK293 cells with an EC50 of 2.5 uM and 8.8 uM, respectively, thereby showing activity through the NO/cGMP pathway. NO levels in ICB and cGMP levels in ICB and aqueous humor were elevated by PF-3187207 following topical administration. These data indicate release and pharmacological activity of NO. The compound lowered IOP more effectively than latanoprost in three hypertensive animal models. In primates, a maximum decrease in IOP of 29% and 23% relative to vehicle was achieved by a single topical dose of 9 and 36 ug PF-3187207, respectively. In comparison, the peak response to latanoprost was 18% relative to vehicle obtained with a 30 ug dose. In glaucomatous Beagles, IOP decreased by 44% and 10% from baseline following a single 15 ug topical dose and vehicle, respectively. Latanoprost at the same dose lowered IOP by 27%, vehicle by 9%. Intracameral injection of hypertonic saline into rabbit eyes increased IOP transiently. Topical latanoprost did not affect this response, as expected, whereas topical PF-3187207 (30 ug) significantly blunted the hypertensive phase.
In three hypertensive animal models PF-3187207 lowered IOP more efficaciously than the reference drug latanoprost presumably as a consequence of a contribution by NO in addition to its prostaglandin activity. The compound is now in clinical development for the treatment of glaucoma and ocular hypertension.
This PDF is available to Subscribers Only